DUPLEX
2023
Sparsentan in Focal Segmental Glomerulosclerosis
In 371 patients with focal segmental glomerulosclerosis, sparsentan reduced proteinuria but did not significantly improve eGFR slope compared with irbesartan.
Result
Primary endpoint: eGFR slope over 108 weeks
Total-slope difference +0.3 mL/min/1.73m²/yr (95% CI −1.7 to 2.4; primary eGFR-slope endpoint missed); FSGS partial remission 42.0% vs 26.0% (p=0.009).
- Subtopic
- FSGS
- Design
- Phase 3 active-controlled RCT
- Relevance
- Supporting: context rather than must-know.
- Source
- Rheault MN, et al. N Engl J Med. 2023;389(26):2436-2445.doi 10.1056/NEJMoa2308550
Discussion & critique
A clean example of proteinuria reduction without an eGFR-slope benefit; no FSGS approval, unlike for IgA nephropathy.